PMC:7275193 / 7469-8049
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T103 | 8-15 | CL:0000763 | denotes | myeloid |
T104 | 19-30 | CL:0000763 | denotes | myelogenous |
T105 | 51-69 | CL:0000763 | denotes | myeloproliferative |
T106 | 116-128 | GO:0065007 | denotes | dysregulated |
T107 | 129-142 | GO:0048468 | denotes | production of |
T108 | 150-163 | CL:0000763 | denotes | myeloid cells |
T109 | 172-184 | CL:0000094 | denotes | granulocytes |
T110 | 318-322 | PR:000003582 | denotes | ABL1 |
T111 | 329-333 | SO:0000704 | denotes | gene |
T112 | 351-355 | PR:000003582 | denotes | ABL1 |
T113 | 485-495 | CHEBI:38637;CHEBI:38637 | denotes | inhibitors |
T114 | 511-520 | CHEBI:5291;CHEBI:5291 | denotes | dasatinib |
T115 | 522-531 | CHEBI:17154;CHEBI:17154 | denotes | nilotinib |
T116 | 537-546 | CHEBI:39112;CHEBI:39112 | denotes | bosutinib |
T92873 | 8-15 | CL:0000763 | denotes | myeloid |
T80530 | 19-30 | CL:0000763 | denotes | myelogenous |
T86107 | 51-69 | CL:0000763 | denotes | myeloproliferative |
T56738 | 116-128 | GO:0065007 | denotes | dysregulated |
T82747 | 129-142 | GO:0048468 | denotes | production of |
T78109 | 150-163 | CL:0000763 | denotes | myeloid cells |
T29288 | 172-184 | CL:0000094 | denotes | granulocytes |
T73235 | 318-322 | PR:000003582 | denotes | ABL1 |
T551 | 329-333 | SO:0000704 | denotes | gene |
T43325 | 351-355 | PR:000003582 | denotes | ABL1 |
T25827 | 485-495 | CHEBI:38637;CHEBI:38637 | denotes | inhibitors |
T2859 | 511-520 | CHEBI:5291;CHEBI:5291 | denotes | dasatinib |
T30323 | 522-531 | CHEBI:17154;CHEBI:17154 | denotes | nilotinib |
T65535 | 537-546 | CHEBI:39112;CHEBI:39112 | denotes | bosutinib |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T31 | 150-163 | Body_part | denotes | myeloid cells | http://purl.org/sig/ont/fma/fma70339 |
T32 | 158-163 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T33 | 172-184 | Body_part | denotes | granulocytes | http://purl.org/sig/ont/fma/fma62854 |
T34 | 220-231 | Body_part | denotes | chromosomal | http://purl.org/sig/ont/fma/fma67093 |
T35 | 283-293 | Body_part | denotes | chromosome | http://purl.org/sig/ont/fma/fma67093 |
T36 | 329-333 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
T37 | 363-370 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T38 | 385-393 | Body_part | denotes | tyrosine | http://purl.org/sig/ont/fma/fma82768 |
T39 | 469-477 | Body_part | denotes | Tyrosine | http://purl.org/sig/ont/fma/fma82768 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T41 | 31-39 | Phenotype | denotes | leukemia | http://purl.obolibrary.org/obo/HP_0001909 |
T42 | 70-78 | Phenotype | denotes | neoplasm | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T79 | 19-39 | Disease | denotes | myelogenous leukemia | http://purl.obolibrary.org/obo/MONDO_0004643 |
T80 | 31-39 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
T81 | 41-44 | Disease | denotes | CML | http://purl.obolibrary.org/obo/MONDO_0001014|http://purl.obolibrary.org/obo/MONDO_0011996 |
T83 | 51-78 | Disease | denotes | myeloproliferative neoplasm | http://purl.obolibrary.org/obo/MONDO_0020076 |
T84 | 70-78 | Disease | denotes | neoplasm | http://purl.obolibrary.org/obo/MONDO_0005070|http://purl.obolibrary.org/obo/MONDO_0021079 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T103 | 49-50 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T104 | 158-163 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
T105 | 252-254 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
T106 | 329-333 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T107 | 401-409 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T108 | 418-421 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T49 | 363-370 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T50 | 385-393 | Chemical | denotes | tyrosine | http://purl.obolibrary.org/obo/CHEBI_18186 |
T51 | 469-495 | Chemical | denotes | Tyrosine kinase inhibitors | http://purl.obolibrary.org/obo/CHEBI_38637 |
T52 | 469-477 | Chemical | denotes | Tyrosine | http://purl.obolibrary.org/obo/CHEBI_17895|http://purl.obolibrary.org/obo/CHEBI_18186 |
T54 | 485-495 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T55 | 511-520 | Chemical | denotes | dasatinib | http://purl.obolibrary.org/obo/CHEBI_49375|http://purl.obolibrary.org/obo/CHEBI_70839 |
T57 | 522-531 | Chemical | denotes | nilotinib | http://purl.obolibrary.org/obo/CHEBI_52172 |
T58 | 537-546 | Chemical | denotes | bosutinib | http://purl.obolibrary.org/obo/CHEBI_39112 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 394-409 | http://purl.obolibrary.org/obo/GO_0016301 | denotes | kinase activity |
T5 | 478-495 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | kinase inhibitors |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T68 | 0-185 | Sentence | denotes | Chronic myeloid or myelogenous leukemia (CML) is a myeloproliferative neoplasm which is defined as uncontrolled and dysregulated production of mature myeloid cells, mainly granulocytes. |
T69 | 186-414 | Sentence | denotes | It results from acquired abnormal chromosomal translocation, t(9; 22), known as the Philadelphia chromosome, which contains the BCR-ABL1 fused gene and produces BCR-ABL1 fusion protein with abnormal tyrosine kinase activity [6]. |
T70 | 415-468 | Sentence | denotes | It has three phases: chronic, accelerated, and blast. |
T71 | 469-580 | Sentence | denotes | Tyrosine kinase inhibitors (TKIs) such as dasatinib, nilotinib, and bosutinib are the first-line treatment [7]. |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
212 | 318-322 | Gene | denotes | ABL1 | Gene:25 |
213 | 351-355 | Gene | denotes | ABL1 | Gene:25 |
214 | 511-520 | Chemical | denotes | dasatinib | MESH:D000069439 |
215 | 522-531 | Chemical | denotes | nilotinib | MESH:C498826 |
216 | 537-546 | Chemical | denotes | bosutinib | MESH:C471992 |
217 | 0-39 | Disease | denotes | Chronic myeloid or myelogenous leukemia | MESH:D015464 |
218 | 41-44 | Disease | denotes | CML | MESH:D015464 |
219 | 70-78 | Disease | denotes | neoplasm | MESH:D009369 |